Patent EP-2130550-A1 (EP)
Inventor: GUIZANI IKRAM
IPC: A61P35/00
Filed: 2008-06-06
Abstract: Use of a DEAD box RNA helicase of yeast/wild mammal, having a mutation in consensus pattern I (SEQ ID NO: 2), or its fragment comprising either six consensus patterns Q (SEQ ID NO: 1), I (SEQ ID NO: 2), Ia (SEQ ID NO: 3), Ib (SEQ ID NO: 4), II (SEQ ID NO: 5) and III (SEQ ID NO: 6) but not the three consensus patterns IV (SEQ ID NO: 7), V (SEQ ID NO: 8) and VI (SEQ ID NO: 9), or three consensus patterns IV, V and VI but not six patterns Q, I, Ia, Ib, II and III, for inducing in vitro/ex vivo production of at least one cytokine by a mononuclear cell of peripheral blood of a mammal, is claimed. Use of a DEAD box RNA helicase of yeast or wild mammal or having a mutation in the consensus pattern I (SEQ ID NO: 2 (comprising Ala-Gln-Ser-Gly-Thr-Gly-Lys-Thr)), or its fragment comprising either six consensus patterns Q (SEQ ID NO: 1 (comprising Gly-Phe-Glu-Glu-Pro-Ser-Ala-Ile-Gln)), I (SEQ ID NO: 2), Ia (SEQ ID NO: 3 (comprising Pro-Thr-Arg-Glu-Leu-Ala)), Ib (SEQ ID NO: 4 (comprising Thr-Pro-Gly-Arg-Val)), II (SEQ ID NO: 5 (comprising Asp-Glu-Ala-Asp)) and III (SEQ ID NO: 6 (comprising Ser-Ala-Thr)) but not the three consensus patterns IV (SEQ ID NO: 7 (comprising Val-Ile-Phe-Cys-Asn-Thr-Arg-Arg-Lys)), V (SEQ ID NO: 8 (comprising Thr-Asp-Leu-Leu-Ala-Arg-Gly-Ile-Asp)) and VI (SEQ ID NO: 9 (comprising His-Arg-Ile-Gly-Arg-Thr-Gly-Arg)), or the three consensus patterns IV, V and VI but not the six patterns Q, I, Ia, Ib, II and III, for inducing the in vitro or ex vivo production of at least one cytokine by a mononuclear cell of the peripheral blood (PBMC) of a mammal, is claimed. Independent claims are included for: (1) a pharmaceutical composition comprising the DEAD box RNA helicase of yeast or mammal or its fragments, and at least one excipient; (2) a first products containing (i) the DEAD box RNA helicase of yeast or mammal or its fragment, (ii) interferon-gamma (IFN-gamma ), for a simultaneous, staggered or sequential use in the treatment or prevention of the cancer and infectious diseases, preferably parasitic infections; (3) a fragment of the protein LEIF of Leishmania infantum, comprising either six consensus patterns Q (SEQ ID NO: 1), I (SEQ ID NO: 2), Ia (SEQ ID NO: 3), Ib (SEQ ID NO: 4), II (SEQ ID NO: 5) and III (SEQ ID NO: 6) but not the three consensus patterns IV (SEQ ID NO: 7), V (SEQ ID NO: 8) and VI (SEQ ID NO: 9), or three consensus patterns IV, V and VI but not the six patterns Q, I, Ia, Ib, II and III and the fragments corresponding to amino acids 1-195 (SEQ ID NO: 17), 1-226 (SEQ ID NO: 18), 1-237 (SEQ ID NO: 19), 25-237 (SEQ ID NO: 20), 26-403 (SEQ ID NO: 21), 129-226 (SEQ ID NO: 22), 129-261 (SEQ ID NO: 23), 196-403 (SEQ ID NO: 24), 237-403 (SEQ ID NO: 25) or 261-403 (SEQ ID NO: 26) of the LEIF protein; and (4) a second products containing (i) the fragment or a protein and (ii) the IFN-gamma , for a simultaneous, sequential or staggered use in the treatment or the prevention of the cancer and infectious diseases, preferably parasitic infections. ACTIVITY : Antimicrobial; Cytostatic; Antiparasitic; Protozoacide. MECHANISM OF ACTION : None given.